Sessions Were Renumbered as of May 19.
Legend:
CC-W = McCormick Place Convention Center, West Building,
CC-N = McCormick Place Convention Center, North Building
H = Hilton Chicago,
UC = Conference Chicago at University Center
* = applied session ! = JSM meeting theme
306
Tue, 8/2/2016,
8:30 AM -
10:20 AM
CC-W181a
SPEED: Advances in Biopharmaceutical Research — Contributed Speed
Biopharmaceutical Section
Chair(s): Madan Gopal Kundu, Novartis Oncology
The Poster portions will take place during Session 213211
and Session 213212
8:35 AM
Generalizing Results from Randomized Trials to Target Population via Weighting Methods Using Propensity Score
—
Ziyue Chen, The Ohio State University ; Eloise Kaizar, The Ohio State University
8:40 AM
Bone Marrow Stromal Cell Therapy for Ischemic Stroke: A Meta-Analysis of Randomized Control Animal Trials
—
Qing Wu, Nevada Institute of Personalized Medicine ; Yuexiang Wang, Mayo Clinic ; Bart Demaerschalk, Mayo Clinic ; Saruna Ghimire, Nevada Institute of Personalized Medicine ; Kay Wellik, Mayo Clinic ; Wenchun Qu, Mayo Clinic
8:50 AM
Stepped Wedge Cluster Randomized Controlled Trials with Two Layers of Clustering: Designs and Comparisons of Power
—
Ranran Dong, The Ohio State University ; Abigail Shoben, The Ohio State University
8:55 AM
On the Use of Nonparametric Tests for Comparing Immunological Reverse Cumulative Distribution Curves (RCDCs)
—
Lihan Yan, FDA ; Bob Small, Sanofi Pasteur ; Ayca Ozol-Godfrey, Sunovion Pharmaceuticals
9:05 AM
Impact of Mis-Specified Prior on the Bayesian Dose-Finding Method in Phase I Cancer Trials
—
Lixia Pei, Janssen R&D ; Kevin Liu, Janssen R&D ; Hong Tian, Janssen R&D
9:10 AM
Covariate Adjustment for Logistic Regression Analysis of Binary Clinical Trial Data
—
Honghua Jiang ; Pandurang Kulkarni, Eli Lilly and Company ; Craig Mallinckrodt, Eli Lilly and Company ; Linda Shurzinske, Eli Lilly and Company ; Geert Molenberghs, Universiteit Hasselt ; Ilya Lipkovich, Quintiles
9:15 AM
Improving Vaccine Inventory Utilization Using R-Based Statistical Heuristic Algorithm
—
Hesham Fahmy, Merck
9:20 AM
Value-Driven Decision Making at Late Stage of Drug Development: Statistical Simulation Approach
—
Masanori Ito, Astellas Pharma ; Hideki Hirooka, Astellas Pharma
9:30 AM
D-Optimal Designs for Multinomial Logistic Models
—
Xianwei Bu, UIC ; Jie Yang, University of Illinois at Chicago
9:35 AM
Finding Minimum Effective Dose With Multiple Testing Procedures
—
Lucy Kerns, Youngstown State University ; Flora Opoku Asantewaa, Youngstown State University
9:45 AM
Comparisons of Statistical Approaches and Procedures in Building Predicting Models to Drug Response from SNPs Through Simulation
—
Wencan Zhang, Takeda Development Center ; Pingye Zhang, University of Southern California ; Feng Gao, Takeda
9:50 AM
Finding the 'Missing Heritability' in Combined Phase 2 and Subset Phase 3 Analyses
—
Knut Wittkowski, Rockefeller University ; Benedetta Bigio, Rockefeller University
9:55 AM
The Analysis of Impact of Difference in Duration of Treatment
—
Jiejun Du, Merck
10:05 AM
Multiple Testing Procedures Under Group Sequential Design
—
Aiying Chen, Temple University
10:10 AM
Use of the Treatment-Free Interval in Driving Decision Making in Cancer Care: A Late-Phase Example
—
Suddhasatta Acharyya, Novartis ; Ashok Panneerselvam, Novartis Oncology ; Sofia Paul, Novartis
